|
Gerry Shaw, Ph.D.
University of Florida
Gainesville, FL
Title:
Blood And CSF Biomarkers Of Alzheimer's Disease
Non-Technical Title:
Monitoring Alzheimer's Disease
Duration:
April 1, 2009 - March 31, 2011
|
Summary: Alzheimer's disease is difficult to diagnose and it is also difficult to monitor the progression of the disease. We have developed two assays which can be used to monitor neurodegeneration using blood and cerebrospinal fluid (CSF) samples. The aim of the present proposal is to see if these assays can be used to monitor Alzheimer's disease.
More details
Program: Alzheimer's Disease
Award Type: Pilot
$150,000
|
|
Jane Sullivan, Ph.D.
University of Washington
Seattle, WA
Title:
Role of Presenilin in Synaptic Transmission
Non-Technical Title:
Understanding synaptic events that precede nerve cell death
Duration:
April 1, 2007 - March 31, 2010
|
Summary: Identifying specific changes in synaptic function produced by mutant presenilin, a protein strongly implicated in the inherited form of Alzheimer’s disease, will provide molecular targets for novel therapies to improve cognitive function and delay further neurodegeneration in patients with early Alzheimer’s disease
More details
Program: Alzheimer's Disease
Award Type: Pilot
$149,950
|
Gopal Thinakaran, Ph.D.
University of Chicago
Chicago, IL
Title:
Microdomain Localization And Trafficking Of BACE1
Non-Technical Title:
Understanding The Mechanisms Of Alzheimer's Disease Amyloid Production
Duration:
April 1, 2009 - March 31, 2012
Co-Investigator(s):
Angele Parent, Ph.D.
University of Chicago
|
Summary: This proposal investigates BACE1, one of the enzymes critical for the production of Alzheimer's disease amyloid beta production. We are interested in deciphering the molecular principles of BACE1 trafficking in lipid rafts and non-raft domains using biochemical and live cell imaging approaches in order to elucidate the cell biology of BACE1 processing of amyloid precursor protein (APP). Our studies will uncover novel and significant basic insights into cellular processes that modulate amyloid beta production, thus contributing to the development of strategies aimed at reducing amyloid beta burden.
More details
Program: Alzheimer's Disease
Award Type: Standard
$400,000
|
Linda Van Eldik, Ph.D.
Northwestern University
Evanston, IL
Title:
Attenuating proinflammatory cytokine up-regulation as an AD therapeutic strategy
Non-Technical Title:
Testing novel CNS therapeutics for efficacy
Duration:
April 1, 2008 - March 31, 2011
|
Summary: The hypothesis to be tested in this project is that orally delivered drugs that inhibit the immune response by activated glia can reduce Alzheimer's related neurodegeneration.
More details
Program: Alzheimer's Disease
Award Type: Standard
$400,000
|
Ruben Vidal, Ph.D.
Indiana University School of Medicine
Indianapolis, IN
Title:
Double transgenic model of familial Danish dementia with plaques and tangles
Non-Technical Title:
Amyloid and tau deposition in the brain of a transgenic mouse model for familial Danish dementia
Duration:
April 1, 2008 - March 31, 2010
|
Summary: Familial Danish Dementia (FDD) is similar clinically and pathologically to AD. The aim of this pilot proposal is to develop a double transgenic animal model of FD. These mice will be used to study the deposition of the Danish amyloid peptide and tau and compare these to similar processes in Alzheimer's disease.
More details
Program: Alzheimer's Disease
Award Type: Pilot
$100,000
|
Youssef Wadghiri, Ph.D.
New York University School of Medicine
New York, NY
Title:
Improving Delivery And Labeling Efficiency Of MRI Probes For Alzheimer's Plaques
Non-Technical Title:
MRI visualization of Alzheimer's plaques
Duration:
April 1, 2008 - March 31, 2010
|
Summary: This project aims to develop safe MRI molecular probes to visualize amyloid ß (Aß) plaques, one of the earliest pathological hallmark of Alzheimer's disease that can only be confirmed by post-mortem examination of the brain. New and future therapeutic approaches may be most effective in preventing the irreversible neuronal damage when employed early in the progression of the disease. This project seeks to develop tools allowing for early diagnosis.
More details
Program: Alzheimer's Disease
Award Type: Pilot
$150,000
|
Ning Wang, Ph.D.
Northwestern University
Evanston, IL
Title:
Compartment And Tissue Specific Toxicity Of Amyloid Beta 1-42 In C. Elegans
Non-Technical Title:
A Story From The Humanized Worms: Comprehensive Study Of Cellular Toxicity Of Amyloid Beta 1-42
Duration:
April 1, 2009 - March 31, 2011
Mentor:
Richard Morimoto, Ph.D.
Northwestern University
|
Summary: What is the cellular basis of amyloid beta toxicity in different cellular compartments and tissue types? What, if any, are the compartment and tissue specific signaling pathways and genetic networks that are involved in modulating amyloid beta toxicity? Is it possible to regulate these genetic networks to provide insight into therapeutic design?
More details
Program: Alzheimer's Disease
Award Type: Research Fellowship
$100,000
|
|
Chunyu Wang, M.D., Ph.D.
Rensselaer Polytechnic Institute
Troy, NY
Title:
Structural Basis Of FAD Mutations Within The Transmembrane Domain Of APP
Non-Technical Title:
Structural Biology Of Amyloid Beta Generation
Duration:
April 1, 2009 - March 31, 2011
|
Summary: This project aims to define the structural characteristics of trans-membrane portion of Amyloid Precursor Protein (APPTM
) as a gamma-secretase substrate that plays a role in determining the amyloid beta 42/amyloid beta 40 ratio. This will be achieved by combining a gamma-secretase assay and structural determination of normal and a variety of mutant forms of APPTM.
More details
Program: Alzheimer's Disease
Award Type: Pilot
$150,000
|
Donald Weaver, M.D., Ph.D.
Dalhousie University
Halifax, Nova Scotia, Canada
Title:
New Anti-Aggregating Drugs Against Alzheimer's Disease
Non-Technical Title:
Drug discovery in AD
Duration:
April 1, 2007 - December 31, 2009
Co-Investigator(s):
Ottavio Arancio, M.D., Ph.D.
Columbia University Medical Center
Edwin De Pauw, Ph.D.
Université de Liège
|
Summary: The ultimate goal of this research project is to discover and optimize a useful drug for the treatment of AD. This drug discovery goal will be addressed by optimizing and advancing into animal models recently-developed small organic molecules ('bi-aromatics') capable of binding to and modulating the aggregation of all three amyloidogenic proteins implicated in AD, i.e. ABeta , tau and -synuclein.
More details
Program: Alzheimer's Disease
Award Type: Centennial
$1,000,000
|
Carmen Westerberg, Ph.D.
Northwestern University
Evanston, IL
Title:
Connections Between Memory Dysfunction and Sleep in Alzheimer's Disease
Non-Technical Title:
Does Poor Sleep Contribute to Poor Memory in Alzheimer's Disease?
Duration:
April 1, 2008 - March 31, 2010
Mentor:
Ken Paller, Ph.D.
Northwestern University
|
Summary: The proposal aims to investigate whether mild cognitive impairment (MCI) is associated with sleep deficits greater than expected due to those accompanying aging alone. It will assess whether sleep performance will predict performance on a test of declarative memory for items learned the day before.
More details
Program: Alzheimer's Disease
Award Type: Research Fellowship
$100,000
